Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Medis","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lupin Signs Distribution Agreement with Medis for Orphan Drug NaMuscla\u00ae","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"SLOVENIA","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Medis

    Menu

    Medis

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Medis

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Slovenia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lupin Signs Distribution Agreement with Medis for Orphan Drug NaMuscla®

              Details:

              Under the agreement announced today, Medis will initially focus on the commercialization of NaMuscla® in the Central and East European countries, namely Croatia, Czech Republic, Hungary, Slovakia, and Slovenia in the first phase.

              Lead Product(s): Mexiletine

              Therapeutic Area: Musculoskeletal Product Name: NaMuscla

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Lupin Ltd

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement February 09, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY